CCL17 and lung cancer: As shown in Table 1, CCL17 high expression was significantly correlated with good prognosis of lung cancer patients at stage 1 (OS, HR = 0.59 (0.45–0.78), p = 0.00018; PFS, HR = 0.55 (0.36–0.85), p = 0.0064) but did not significantly correlate with OS and PFS in patients with lung cancer at stage 2–4.